Soligenix

Soligenix initiates a double-blind, multi-centre Phase III trial of HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL), building on a previous study showing a 49% treatment response after 18 weeks. The FLASH2 trial, extending treatment to 18 weeks, aims to confirm HyBryte's effectiveness.

Soligenix initiated Phase 3 FLASH2 trial of HyBryte in CTCL, with extended treatment period. HyBryte showed continued improvement post-treatment in a comparator trial. Phase 2 trial of SGX945 for Behcet’s disease also initiated. Valuation remains at $35 per share.

Soligenix opens patient enrollment for FLASH2, a Phase 3 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL). The study builds on previous successful trials and aims to demonstrate HyBryte™'s efficacy over 18 weeks of continuous treatment.

Soligenix opens patient enrollment for FLASH2 Phase 3 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL), building on previous successful studies. The study aims to demonstrate HyBryte™'s efficacy over 18 weeks of continuous treatment, with interim analysis expected in early 2026.

Soligenix opens patient enrollment for FLASH2 Phase 3 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL), building on previous successful studies. The study aims to demonstrate HyBryte's™ efficacy over an 18-week continuous treatment period, with enrollment expected in the U.S. and Europe, and a formal interim analysis anticipated in early 2026.

Soligenix announces continued improvement in HyBryte™-treated patients and lesions post-treatment, with statistically significant efficacy against plaque lesions compared to Valchlor®, and no safety concerns raised.

FDA approves Journey Medical’s DFD-29 for rosacea, PDUFA dates set for tapinarof cream, pz-cel, and dupilumab, bimekizumab approved for HS, rademikibart shows enhanced IL-4Rα inhibition, VYN201 safe for vitiligo, clascoterone cream stable with acne treatments, MJH Life Sciences acquires RAD conference, ILDS awards young dermatologists, Concerto Biosciences starts ENS-002 trial, Soligenix launches HyBryte CTCL trial advisory board, Protagonist introduces PN-881, SCAN project trains cosmetologists for skin cancer detection, CAB gel effective for Hispanic acne patients, study highlights diversity gaps in nursing textbooks.

Soligenix forms European Medical Advisory Board for HyBryte's CTCL development, guided by experts like Martine Bagot, Pietro Quaglino, and Pablo Luis Ortiz-Romero. The phase 3 FLASH2 trial aims to extend treatment to 18 weeks, enrolling 80 patients across the US and Europe, with primary endpoint measuring lesion severity reduction. HyBryte, activated by visible light, targets malignant T-cells, showing efficacy in previous trials and potential for broader therapeutic use.

Soligenix forms European Medical Advisory Board to guide Phase 3 study of HyBryte™ in CTCL, targeting enrollment of 80 patients in U.S. and Europe by end of 2024, with results expected in 2026.